Rhinopront

Carbinoxamine:

• Rhinopront (Carbinoxamine) reviews

Rhinopront (Carbinoxamine) is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for Rhinopront (Carbinoxamine) as an over the counter cough and cold medicine is being modified to state “do not use” in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks.

Indication: For symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis, as well as allergic conjunctivitis caused by foods and inhaled allergens. Also for the relief of allergic reactions to blood or plasma, and the symptomatic management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema.

Rhinopront (Carbinoxamine) is a first generation antihistamine of the ethanolamine class. Ethanolamine antihistamines have significant antimuscarinic activity and produce marked sedation in most patients. In addition to the usual allergic symptoms, the drug also treats irritant cough and nausea, vomiting, and vertigo associated with motion sickness. It also is used commonly to treat drug-induced extrapyramidal symptoms as well as to treat mild cases of Parkinson's disease. Rather than preventing the release of histamine, as do cromolyn and nedocromil, Rhinopront (Carbinoxamine) competes with free histamine for binding at HA-receptor sites. Rhinopront (Carbinoxamine) competitively antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Ethanolamine derivatives have greater anticholinergic activity than do other antihistamines, which probably accounts for the antidyskinetic action of Rhinopront (Carbinoxamine).

Phenylpropanolamine:

• Rhinopront (Phenylpropanolamine) reviews

Rhinopront (Phenylpropanolamine) has been withdrawn in Canada. In November 2000, the Food and Drug Administration (FDA) issued a public health advisory against the use of the drug.

Indication: For the treatment of nasal congestion, control of urinary incontinence, priapism and obesity.

Rhinopront (Phenylpropanolamine) (PPA), a sympathomimetic agent structurally similar to pseudoephedrine, is used to treat nasal congestion. Rhinopront (Phenylpropanolamine) is found in appetite suppressant formulations and with guaifenesinin in cough-cold formulations. In 2000, the FDA requested that all drug companies discontinue marketing products containing Rhinopront (Phenylpropanolamine), due to an increased risk of hemorrhagic stroke in women who used Rhinopront (Phenylpropanolamine).